{
  "abstract": "Sexually transmitted infections (STIs) remain a major global public health challenge, affecting all regions and disproportionately impacting women, adolescents, key populations and people living in resource-constrained settings. The WHO estimated in 2020 that approximately 374 million new curable infections (chlamydia, gonorrhoea, syphilis and trichomoniasis) occur among adults aged 15–49 years annually, alongside lifelong viral infections such as HIV, herpes simplex virus and human papillomavirus (HPV).1 STIs are well-established causes of infertility, adverse pregnancy outcomes, neonatal morbidity, malignancies and amplified HIV transmission, and they evoke stigma, discrimination and psychosocial distress. For several STI pathogens, antimicrobial resistance (AMR) substantially threatens effective treatment and care, and global surveillance of AMR is crucial.2 3 The cumulative impact of STIs, therefore, extends beyond individual morbidity to broader population-level consequences for health and well-being.",
  "authors": [
    {
      "affiliations": [
        "HIV, TB, Hepatitis and STIs, WHO, Geneva, Switzerland"
      ],
      "name": "Ismael Maatouk"
    },
    {
      "affiliations": [
        "HIV, TB, Hepatitis and STIs, WHO, Geneva, Switzerland"
      ],
      "name": "Daniel McCartney"
    },
    {
      "affiliations": [
        "WHO, Geneva, Switzerland"
      ],
      "name": "Teodora Wi"
    },
    {
      "affiliations": [
        "Skin and Genitourinary Medicine Clinic, Harare, Zimbabwe"
      ],
      "name": "Francis Ndowa"
    },
    {
      "affiliations": [
        "WHO Collaborating Centre for Gonorrhoea and Other STIs, Örebro University, Örebro, Sweden",
        "Institute for Global Health, University College London, London, UK"
      ],
      "name": "Magnus Unemo"
    }
  ],
  "title": "Evolving global sexually transmitted infection guidance: translating evidence-based WHO recommendations into clinical practice",
  "uid": "ad908afe-39df-5407-b8f7-51b634a7dab1"
}